Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

BLOOD COMMENTARIES

PLENARY PAPER

The World Health Organization’s classification of hematopoietic and lymphoid tumors has worked to integrate morphology and genetics, but del(5q) remains the only molecularly defined subtype of myelodysplasia (MDS). In a Special Report that is also this issue’s Plenary Paper, the International Working Group for the Prognosis of MDS makes the case for designating SF3B1-mutant MDS as a second molecularly defined subtype with good prognosis and increased likelihood of response to luspatercept.

CLINICAL TRIALS AND OBSERVATIONS

Bianca Rocca,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Alberto Tosetto,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Silvia Betti,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Denise Soldati,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Giovanna Petrucci,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Elena Rossi,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Andrea Timillero,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Viviana Cavalca,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Benedetta Porro,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Alessandra Iurlo,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Daniele Cattaneo,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Cristina Bucelli,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Alfredo Dragani,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Mauro Di Ianni,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Paola Ranalli,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Francesca Palandri,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Nicola Vianelli,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Eloise Beggiato,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Giuseppe Lanzarone,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Marco Ruggeri,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Giuseppe Carli,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Elena Maria Elli,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Monica Carpenedo,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Maria Luigia Randi,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Irene Bertozzi,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Chiara Paoli,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Giorgina Specchia,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Alessandra Ricco,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Alessandro Maria Vannucchi,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Francesco Rodeghiero,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Carlo Patrono,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators,Valerio De Stefano,on behalf of the Aspirin Regimens in Essential Thrombocythemia (ARES) Investigators

Treatment with once-daily aspirin (acetylsalicylic acid [ASA]) is recommended in essential thrombocythemia (ET) based on efficacy studies in polycythemia vera, but ASA may not provide sufficient platelet inhibition in ET because of increased platelet activation. Rocca et al compared efficacy of ASA in suppressing thromboxane excretion with once-, twice-, and 3-times–daily dosing. Twice-daily dosing has superior antiplatelet activity compared to once-daily dosing, with no further improvement with treatment 3 times daily.

HEMATOPOIESIS AND STEM CELLS

Aging-associated changes in hematopoietic stem cells lead to myeloid skewing, anemia of aging, and increased risk of myeloid malignancy. He et al confirmed that these changes are closely linked to increased expression of inflammatory cytokines, demonstrating that an age-associated increase in tumor necrosis factor α leads to increased expression of interleukin 27 receptor α (IL27Ra) and that these IL27Ra+ stem cells have impaired reconstitution capacity and increased myeloid skewing.

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Cristina Perez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Cirino Botta,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Aintzane Zabaleta,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Noemi Puig,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Maria-Teresa Cedena,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Ibai Goicoechea,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Daniel Alameda,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Edurne San José-Eneriz,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Juana Merino,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Paula Rodríguez-Otero,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Catarina Maia,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Diego Alignani,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Patricia Maiso,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Irene Manrique,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,David Lara-Astiaso,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Amaia Vilas-Zornoza,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Sarai Sarvide,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Caterina Riillo,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Marco Rossi,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Laura Rosiñol,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Albert Oriol,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,María-Jesús Blanchard,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Rafael Rios,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Anna Sureda,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Jesus Martin,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Rafael Martinez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Joan Bargay,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Javier de la Rubia,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Miguel-Teodoro Hernandez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Joaquin Martinez-Lopez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Alberto Orfao,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Xabier Agirre,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Felipe Prosper,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Maria-Victoria Mateos,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Juan-José Lahuerta,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Joan Blade,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Jesús F. San-Miguel,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group,Bruno Paiva,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group

Myeloid-derived suppressor cells (MDSCs) are a subset of mature neutrophils that promote tumor growth through suppression of T-cell responses. Perez et al characterize MDSCs in multiple myeloma, proposing a combination of markers to identify this subpopulation and correlating their frequency with inferior progression free survival.

LYMPHOID NEOPLASIA

Stromal adhesion mediated by integrin α6 has been implicated in both drug resistance and central nervous system migration of B-cell acute lymphoblastic leukemia (B-ALL) cells. The authors demonstrated that blocking α6 induces apoptosis in B-ALL cells and increases their sensitivity to chemotherapy, suggesting that α6 is a potential novel target for B-ALL therapy.

MYELOID NEOPLASIA

Acute myeloid leukemia (AML) associated with inv(3)/t(3;3) is recognized as a distinct form of AML associated with poor prognosis. Ottema and colleagues dissected the genotypic and functional characteristics of atypical 3q26/MECOM rearrangements in AML, demonstrating that they have a similar pattern of gene expression to inv(3)/t(3;3) and suggesting that all 3q26-rearranged AML should be viewed as a single entity.

RED CELLS, IRON, AND ERYTHROPOIESIS

Chen and colleagues present a novel paradigm of the role of erythropoietin (Epo) in stress hematopoiesis. Using a mouse model, they demonstrated that Epo acts to modulate macrophages in the erythropoietic niche to suppress Wnt expression, suppressing Wnt-induced proliferation of early progenitors, and to increase production of prostaglandin E2, inducing erythroid progenitors to differentiate.

THROMBOSIS AND HEMOSTASIS

Garnier and colleagues studied erythrocyte-derived microparticles (MPs) isolated from the plasma of patients with sickle cell disease (SCD) before and after hydroxyurea treatment and during vaso-occlusive crisis. They demonstrated that increased phosphatidylserine (PS) expression on SCD MPs increases endothelial ICAM-1 and neutrophil adhesion at baseline, and this was markedly increased during crisis. Furthermore, PS expression was decreased by hydroxyurea, suggesting a novel effect in preventing crisis.

BLOOD WORK

ERRATA

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals